These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 16447241)

  • 21. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DMARDS and infections in rheumatoid arthritis.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Montecucco C
    Autoimmun Rev; 2008 Dec; 8(2):139-43. PubMed ID: 19014871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of infection in rheumatoid arthritis.
    Doran MF; Crowson CS; Pond GR; O'Fallon WM; Gabriel SE
    Arthritis Rheum; 2002 Sep; 46(9):2294-300. PubMed ID: 12355476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.
    Antohe JL; Bili A; Sartorius JA; Kirchner HL; Morris SJ; Dancea S; Wasko MC
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):215-21. PubMed ID: 21972198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient preferences for treatment of rheumatoid arthritis.
    Fraenkel L; Bogardus ST; Concato J; Felson DT; Wittink DR
    Ann Rheum Dis; 2004 Nov; 63(11):1372-8. PubMed ID: 15020312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
    Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
    Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
    Wolfe F; Michaud K
    Arthritis Rheum; 2008 Sep; 58(9):2612-21. PubMed ID: 18759273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.
    Bernatsky S; Hudson M; Suissa S
    Rheumatology (Oxford); 2007 Jul; 46(7):1157-60. PubMed ID: 17478469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antirheumatic drug use and the risk of acute myocardial infarction.
    Suissa S; Bernatsky S; Hudson M
    Arthritis Rheum; 2006 Aug; 55(4):531-6. PubMed ID: 16874796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
    Wolfe F; Hawley DJ
    J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
    Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
    Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
    Sakai R; Komano Y; Tanaka M; Nanki T; Koike R; Nagasawa H; Amano K; Nakajima A; Atsumi T; Koike T; Ihata A; Ishigatsubo Y; Saito K; Tanaka Y; Ito S; Sumida T; Tohma S; Tamura N; Fujii T; Sugihara T; Kawakami A; Hagino N; Ueki Y; Hashiramoto A; Nagasaka K; Miyasaka N; Harigai M;
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1125-34. PubMed ID: 22422487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
    Ostör AJ; Chilvers ER; Somerville MF; Lim AY; Lane SE; Crisp AJ; Scott DG
    J Rheumatol; 2006 Mar; 33(3):622-8. PubMed ID: 16511933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.